AMA says obesity is a disease but the decision is up for debate
In July, the American Medical Association (AMA) announced the recommendation to reclassify obesity from a disorder to a disease.
“For some, the question might be characterized as whether obesity is a disease that requires a treatment or is it due to personal behavior-overeating, lack of exercise and physical activity,” says Joel Brill, MD, MHE editorial advisor and chief medical officer of Predictive Health LLC. “If patients assume a sick role-‘I am obese, I have a disease’-how does that impact personal responsibility?”
About 60% of Americans are overweight or obese. Research has shown that by 2022, 81 million Americans are estimated to be overweight and 113 million obese.
The AMA’s Council on Science and Public Health says, “Given the existing limitations of BMI [body mass index] to diagnose obesity in clinical practice, it is unclear that recognizing obesity as a disease, as opposed to a ‘condition’ or ‘disorder,’ will result in improved health outcomes.”
Obesity alone causes 200,000 deaths annually and is more prevalent than tobacco use. It also accounts for $147 billion to $210 billion in costs annually, according to the Trust for America’s Health. Combined with overweight, it is the second leading cause of preventable death in the United States.
“Obviously, this is a complex issue from a coverage perspective with impact on purchasers, payers, providers and of course patients that could take time to address what types of services-drugs and devices-are medically necessary and should be covered,” says Dr. Brill.
He also says the designation might make payers and Medicare reassess coverage positions toward drugs, surgery, dietician counseling and/or minimally invasive trans-oral devices for obesity. Whether or not the designation will have an effect on these devices for people who are overweight but not morbidly obese is a big question.
“Will plans pay for obesity devices in a patient who is 50, 70, 90 pounds overweight?” he asks. “What if the patient loses 50 to 80 pounds and wants the device removed-would that [procedure] be a covered benefit? And if the patient needs a device years later, would that be covered?”
Plans are required under health reform to cover certain preventive services recommended by the United States Preventative Task Force (USPTF) without imposing a copayment, including programs for adults needing assistance with smoking cessation and substance abuse. USPTF also has coverage recommendations for obesity in adults and children.
All adults and children, age six and older, are recommended for obesity screening. USPTF says clinicians should offer or refer patients with a body mass index of 30 or higher to intensive, multicomponent behavioral interventions. It is recommended that obese children be referred to comprehensive, intensive behavioral interventions to promote improvement in weight status.
When it comes to coverage, Dr. Brill recommends that plans take it a step further.
“Pay for nutritional counseling and follow-up,” he says. “Teach people how to shop and purchase food in a responsible manner.”
He also recommends covering kinesiologist and trainer visits so members can be assessed and participate in home exercise programs.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More